BR112022013673A2 - Inibidores de ahr e seus usos - Google Patents
Inibidores de ahr e seus usosInfo
- Publication number
- BR112022013673A2 BR112022013673A2 BR112022013673A BR112022013673A BR112022013673A2 BR 112022013673 A2 BR112022013673 A2 BR 112022013673A2 BR 112022013673 A BR112022013673 A BR 112022013673A BR 112022013673 A BR112022013673 A BR 112022013673A BR 112022013673 A2 BR112022013673 A2 BR 112022013673A2
- Authority
- BR
- Brazil
- Prior art keywords
- ahr
- ahr inhibitors
- inhibitors
- selecting
- positive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959246P | 2020-01-10 | 2020-01-10 | |
| US202063128465P | 2020-12-21 | 2020-12-21 | |
| PCT/US2021/012571 WO2021142180A1 (en) | 2020-01-10 | 2021-01-08 | Ahr inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022013673A2 true BR112022013673A2 (pt) | 2022-09-13 |
Family
ID=74595366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022013673A BR112022013673A2 (pt) | 2020-01-10 | 2021-01-08 | Inibidores de ahr e seus usos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230039711A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4087578A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023510797A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220125323A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115190799A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021206696A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022013673A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3167283A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2022001872A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL294647A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022008532A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021142180A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019012431A (es) | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
| AU2020394424A1 (en) | 2019-11-26 | 2022-06-16 | Ikena Oncology, Inc. | Polymorphic carbazole derivatives and uses thereof |
| WO2021236717A1 (en) | 2020-05-20 | 2021-11-25 | Senda Biosciences, Inc. | Fused imidazole derivatives as ahr antagonists |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10314810B2 (en) * | 2010-07-27 | 2019-06-11 | Trustees Of Boston University | Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics |
| HK1201471A1 (en) * | 2011-09-07 | 2015-09-04 | Deutsches Krebsforschungszentrum | Means and methods for treating and/or preventing natural ahr ligand-dependent cancer |
| SG11201810366WA (en) | 2016-05-25 | 2018-12-28 | Bayer Pharma AG | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides |
| WO2018085348A1 (en) | 2016-11-03 | 2018-05-11 | Actavalon, Inc. | Substituted quinolines and methods for treating cancer |
| MX2019012431A (es) | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
| CN111163766A (zh) | 2017-08-17 | 2020-05-15 | 医肯纳肿瘤学公司 | Ahr抑制剂和其用途 |
| WO2019101642A1 (en) | 2017-11-21 | 2019-05-31 | Bayer Aktiengesellschaft | Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides |
| US11524944B2 (en) | 2017-11-21 | 2022-12-13 | Bayer Aktiengesellschaft | 2-phenylpyrimidine-4-carboxamides as AHR inhibitors |
| EP3713926B1 (en) | 2017-11-21 | 2023-06-07 | Bayer Aktiengesellschaft | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists |
| EP3713931B1 (en) | 2017-11-21 | 2025-03-05 | Deutsches Krebsforschungszentrum | 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides |
| JP2021536458A (ja) | 2018-09-04 | 2021-12-27 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | アリール炭化水素レセプター・アンタゴニスト及び使用方法 |
| KR20210110566A (ko) | 2018-10-16 | 2021-09-08 | 이케나 온콜로지, 인코포레이티드 | 인돌 ahr 저해제 및 이의 용도 |
| CA3115825A1 (en) | 2018-10-17 | 2020-04-23 | Magenta Therapeutics, Inc. | Methods of treating cancer with aryl hydrocarbon receptor antagonists |
-
2021
- 2021-01-08 BR BR112022013673A patent/BR112022013673A2/pt not_active IP Right Cessation
- 2021-01-08 KR KR1020227027399A patent/KR20220125323A/ko not_active Withdrawn
- 2021-01-08 WO PCT/US2021/012571 patent/WO2021142180A1/en not_active Ceased
- 2021-01-08 AU AU2021206696A patent/AU2021206696A1/en not_active Abandoned
- 2021-01-08 EP EP21705294.3A patent/EP4087578A1/en not_active Withdrawn
- 2021-01-08 US US17/791,608 patent/US20230039711A1/en not_active Abandoned
- 2021-01-08 CN CN202180014318.3A patent/CN115190799A/zh not_active Withdrawn
- 2021-01-08 IL IL294647A patent/IL294647A/en unknown
- 2021-01-08 CA CA3167283A patent/CA3167283A1/en active Pending
- 2021-01-08 JP JP2022542408A patent/JP2023510797A/ja not_active Withdrawn
- 2021-01-08 MX MX2022008532A patent/MX2022008532A/es unknown
-
2022
- 2022-07-08 CL CL2022001872A patent/CL2022001872A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4087578A1 (en) | 2022-11-16 |
| CN115190799A (zh) | 2022-10-14 |
| IL294647A (en) | 2022-09-01 |
| WO2021142180A1 (en) | 2021-07-15 |
| KR20220125323A (ko) | 2022-09-14 |
| US20230039711A1 (en) | 2023-02-09 |
| JP2023510797A (ja) | 2023-03-15 |
| CA3167283A1 (en) | 2021-07-15 |
| AU2021206696A1 (en) | 2022-08-04 |
| CL2022001872A1 (es) | 2023-02-17 |
| MX2022008532A (es) | 2022-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023000687A2 (pt) | Métodos e combinações de inibidores de kat6 para o tratamento de câncer | |
| MX2022012714A (es) | Inhibidores de la replicacion de norovirus y coronavirus. | |
| CO2026004964A2 (es) | Moduladores de kras | |
| BR112018075682A2 (pt) | inibidores de papd5 e papd7 para tratamento de infecção pela hepatite b | |
| MX2023001689A (es) | Inhibidores de bcl-2. | |
| BR112022005896A2 (pt) | Inibidores da mek para o tratamento de infecções causadas por hantavírus | |
| MX2019011221A (es) | Terapia de combinacion para el tratamiento o prevencion de tumores. | |
| MX2020003561A (es) | Inhibicion de la hsd17b13 en el tratamiento de la enfermedad hepatica en pacientes que expresan la variacion pnpla3 i148m. | |
| MX2016011975A (es) | Metodos para reducir el riesgo cardiovascular. | |
| CL2022001872A1 (es) | Inhibidores de ahr y usos de los mismos | |
| BR112016014481A2 (pt) | tratamento de câncer utilizando combinações de inibidores de erk e raf | |
| BR112014019052A8 (pt) | Inibidores seletivos de cdk8/cdk19 e seu uso em métodos antimetastáticos e quimiopreventivos para câncer | |
| MX2022013172A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| CL2022001794A1 (es) | Terapia combinada que comprende inhibidores de a2a/a2b y pd-1/pd-l1. | |
| CL2022002564A1 (es) | Combinaciones de brimonidina de dosis baja y usos de las mismas. (solicitud divisional de 201903572) | |
| MX2017000628A (es) | Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia. | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| MX2019013308A (es) | Composiciones y compuestos terapeuticos, y metodos para su uso. | |
| BR112022017727A2 (pt) | Inibidores de eif4e e usos dos mesmos | |
| MX2018002000A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| CL2022000214A1 (es) | Inhibidores de enzimas | |
| MX2024001540A (es) | Inhibidores para coronavirus. | |
| MX2022005985A (es) | Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo. | |
| CL2020000270A1 (es) | Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2862 DE 11/11/2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS. |